Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     


Delayed Nasdaq  -  04:00:01 2023-02-07 pm EST
1.230 USD   -1.60%
02/02Nrx Pharmaceuticals, Inc. : Other Events (form 8-K)
02/02NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
01/19NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NRx Pharmaceuticals : Announces the Appointment of Stephen Willard, Chief Executive Officer and Director - Form 8-K

07/15/2022 | 05:14pm EST

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

· Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies
· Proven track record of creating value for shareholders
· National Science Board Presidential Appointee, 2018-2024
· Former roles at Federal Deposit Insurance Corporation (FDIC) and E*Trade Financial

RADNOR, Pa., July 13, 2022 /PRNewswire/ - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, today announcedthe appointment of Stephen Willard, as its Chief Executive Officer ("CEO") and a member of the Company's Board of Directors. The Company's interim CEO, Robert Besthof, will continue to support the Company and return to his roles as Head of Operations and Chief Commercial Officer.

"We are delighted to have attracted a candidate like Steve whose background and experience align with NRx Pharmaceuticals' current needs. Steve's passion to provide breakthrough therapies to address critical unmet needs positions the Company for success," said Patrick Flynn, a member of the Company's Board of Directors. "We look forward to Steve's leadership of the Company in the next stages of growth to benefit patients, our shareholders, and the broader NRx team."

Mr. Willard brings a wealth of experience in the management of publicly traded biotechnology companies, together with his background in law and finance. Most recently, Mr. Willard served as CEO of Cellphire Therapeutics, where he grew the company and shepherded their revolutionary human platelet platform through key clinical trials, growing the company and significantly increasing the share price. Prior to Cellphire, he served as CEO of publicly traded Flamel Technologies now known as Avadel Pharmaceuticals. Mr. Willard is currently serving a six-year term from 2018-2024 as a presidential appointee to the National Science Board.

Mr. Willard's career in financial services includes government service as Associate Director of the Federal Deposit Insurance Corporation (FDIC), where he served in the United States Senior Executive Service (SES) from 1991-1994, and on the board of E*Trade Financial Services from 2000-2014. He has practiced law in New York, London, and Washington, D.C. Mr. Willard earned his undergraduate degree from Williams College and attended Yale University where he earned a JD in law.

"I am honored to have been chosen by the NRx Pharmaceuticals Board to lead the Company as it conducts its trials for NRX-101 in the treatment of Suicidal Bipolar Depression and continues to develop its pipeline of drugs for depression, PTSD, and other potential neuroscience indications based on more than 90 issued and pending patents worldwide," said Willard. "The NRx Pharmaceuticals team has built an extraordinary scientific, patent, and regulatory foundation. I look forward to leading the Company, working with Robert and the NRx Pharmaceuticals leadership in its quest to bring NRX-101, a potentially life-saving medicine, to patients."

The Board of NRx Pharmaceuticals thanks Mr. Besthof for having assumed the additional responsibilities as interim CEO during this transition period.

About NRX-101

Up to 50% of individuals with Bipolar Disorder attempt suicide over their lifetime, and estimates indicate that up to 20% may succumb to suicide. The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation and behavior (ASIB) remains electroconvulsive therapy (ECT). Conventional antidepressants can increase the risk of suicide in certain patients, hence their labels contain a warning to that effect. NRX-101 is a patented fixed dose combination of D-cycloserine and Lurasidone, neither of which has shown addiction potential. Based on the results of a Phase II study, NRX-101 received Breakthrough Therapy designation (BTD) from the FDA for the Treatment of Severe Bipolar Depression in Patients with ASIB after initial stabilization with ketamine or other effective therapy.

NRX-101 is one of the first oral antidepressants currently in late stage clinical studies targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, PTSD and other indications. To date, NRX-101 is the only oral NMDA investigational medicine focused on bipolar depression in patients with acute and sub-acute suicidality.

In the coming year, the Company aims to complete the FDA registration trials for NRX-101 under a Special Protocol Agreement (SPA) awarded by the FDA.


About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience applying innovative science to known molecules to address very high unmet needs and bring improved health to patients. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.

Cautionary Note Regarding Forward-Looking Statements

This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management.

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.


Molly Cogan

Sr. Director, Global Communications



Tim McCarthy

Investor Relations


SOURCE: NRx Pharmaceuticals



NRX Pharmaceuticals Inc. published this content on 15 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 July 2022 21:13:04 UTC.

ę Publicnow 2022
02/02Nrx Pharmaceuticals, Inc. : Other Events (form 8-K)
02/02NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial o..
01/19NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Pat..
01/19NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regardi..
01/05NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neu..
01/03Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
01/03Sector Update: Health Care
01/03NRX Pharmaceuticals Contracts First Site for Phase 3 Clinical Trial of Investigational ..
01/03NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression w..
01/03NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depres..
More news
Analyst Recommendations on NRX PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 83,2 M 83,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees -
Free-Float 55,8%
Duration : Period :
NRx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NRX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,23 $
Average target price 3,25 $
Spread / Average Target 164%
Managers and Directors
Stephen H. Willard Chief Executive Officer & Director
Seth L. van Voorhees Chief Financial Officer & Treasurer
Jonathan C. Javitt Chairman
Carrie M. Carretta Senior VP-Clinical Development & Medical Affairs
Robert Besthof Chief Commercial Officer & Head-Operations
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-5.21%65 718
LONZA GROUP AG22.05%44 419
SEAGEN INC.6.95%25 518